Vator Securities Sole Bookrunner in SEK 324 million direct share issue - the largest in Swedish history in a diagnostics company
Vator Securities Sole Bookrunner in successful SEK 324 million direct share issue in Immunovia, the largest ever in a diagnostics company in Sweden.Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. The Share Issue generated strong demand from reputable institutions in Sweden and internationally, such as Swedbank Robur, Handelsbanken Fonder, Alfred Berg